{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T00:20:34Z","timestamp":1795134034373,"version":"4.10.3"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Biliary tract cancers (BTCs) are aggressive malignancies with limited treatment options, especially after first-line chemotherapy failure. FOLFIRINOX, though established for pancreatic cancer, has shown promise in advanced BTC, yet its role as a second-line treatment remains unclear. To address this gap, we conducted a retrospective cohort study to evaluate the efficacy and safety of FOLFIRINOX and performed a systematic review with meta-analysis to compare its outcomes with currently recommended regimens, including FOLFIRI, FOLFOX, and nal-IRI\/FL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We retrospectively analyzed 54 patients with BTC treated with FOLFIRINOX as second-line therapy after progression on first-line chemotherapy at a single tertiary hospital between 2011 and 2022. A systematic review and meta-analysis, registered with PROSPERO, incorporated 21 studies comparing second-line regimens for BTC, assessing progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In our cohort, median PFS and OS were 2 \u00b7 7 and 8 \u00b7 9 months, respectively. ORR was 12 \u00b7 5%, and DCR was 52 \u00b7 1%, with 4 \u00b7 2% achieving complete response. Meta-analysis revealed pooled PFS and OS for FOLFIRINOX at 4 \u00b7 15 and 8 \u00b7 91 months, respectively, suggesting a potential benefit over FOLFIRI and FOLFOX. Grade 3\u20135 neutropenia occurred in 40 \u00b7 7% of patients, leading to dose reductions in 29.6% but low discontinuation rates (3 \u00b7 7%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>FOLFIRINOX demonstrates numerically favorable outcomes compared to current second-line regimens for advanced BTC, with manageable toxicities. These findings suggest FOLFIRINOX as a potential second-line option, warranting further prospective validation and patient selection refinement.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/js9.0000000000003367","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:00:19Z","timestamp":1757080819000},"page":"1775-1786","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Comparison of second-line chemotherapy regimens in advanced biliary tract cancer: a systematic review, meta-analysis, and population-based cohort study"],"prefix":"10.1097","volume":"112","author":[{"given":"Galam","family":"Leem","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihun","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Occupational and Environmental Medicine, Pusan National University Yangsan Hospital, Yangsan, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Seung","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moon Jae","family":"Chung","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Youp","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Woo","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9796-8266","authenticated-orcid":false,"given":"Yun Hak","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Department of Biomedical Informatics, Pusan National University, Yangsan, Republic of Korea"},{"name":"Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Bang","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea"},{"name":"Institute of Gastroenterology Research, Yonsei University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,5]]},"reference":[{"key":"R1-20260518","doi-asserted-by":"crossref","first-page":"1273\u201381","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"R2-20260518","doi-asserted-by":"crossref","first-page":"507\u2013517;discussion517\u2013509","DOI":"10.1097\/00000658-200110000-00010","article-title":"Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma","volume":"234","author":"Jarnagin","year":"2001","journal-title":"Ann Surg"},{"key":"R3-20260518","doi-asserted-by":"crossref","first-page":"1777\u201387","DOI":"10.1007\/s00268-019-04966-4","article-title":"Trends in the incidence, treatment and outcomes of patients with intrahepatic cholangiocarcinoma in the USA: facility type is associated with margin status, use of lymphadenectomy and overall survival","volume":"43","author":"Wu","year":"2019","journal-title":"World J Surg"},{"key":"R4-20260518","doi-asserted-by":"crossref","first-page":"540\u201342","DOI":"10.1002\/ags3.12710","article-title":"Recent progress in the treatment for unresectable biliary tract cancer","volume":"7","author":"Endo","year":"2023","journal-title":"Annals of Gastroenterol Surg"},{"key":"R6-20260518","doi-asserted-by":"crossref","first-page":"1853\u201365","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"R7-20260518","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"key":"R8-20260518","doi-asserted-by":"crossref","first-page":"690\u2013701","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"key":"R9-20260518","doi-asserted-by":"crossref","first-page":"e2019087","DOI":"10.4322\/acr.2019.087","article-title":"FOLFIRI as second-line treatment of metastatic biliary tract cancer patients","volume":"9","author":"Caparica","year":"2019","journal-title":"Autops Case Rep"},{"key":"R10-20260518","doi-asserted-by":"crossref","first-page":"83\u201391","DOI":"10.4251\/wjgo.v12.i1.83","article-title":"Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers","volume":"12","author":"Mizrahi","year":"2020","journal-title":"World J Gastrointest Oncol"},{"key":"R11-20260518","doi-asserted-by":"crossref","first-page":"692\u201399","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol"},{"key":"R12-20260518","doi-asserted-by":"crossref","first-page":"634\u201339","DOI":"10.1038\/s41416-019-0698-9","article-title":"Efficacy and safety of FOLFIRINOX as salvage treatment in advanced biliary tract cancer: an open-label, single arm, phase 2 trial","volume":"122","author":"Belkouz","year":"2020","journal-title":"Br J Cancer"},{"key":"R13-20260518","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.3390\/cancers14081950","article-title":"Modified FOLFIRINOX as a second-line treatment for patients with gemcitabine-failed advanced biliary tract cancer: a prospective multicenter phase II study","volume":"14","author":"Lee","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R14-20260518","first-page":"100082","article-title":"Transparency in the reporting of artificial intelligence\u2013the TITAN guideline","volume":"10","author":"Agha","year":"2025","journal-title":"Prem J Sci"},{"key":"R15-20260518","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R16-20260518","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R17-20260518","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"R18-20260518","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Patricia Guyot","year":"2012","journal-title":"BMC Med Res Method"},{"key":"R19-20260518","doi-asserted-by":"crossref","first-page":"2521\u201337","DOI":"10.1002\/sim.6111","article-title":"Meta-analysis of single-arm survival studies: a distribution-free approach for estimating summary survival curves with random effects","volume":"33","author":"Combescure","year":"2014","journal-title":"Stat Med"},{"key":"R20-20260518","doi-asserted-by":"crossref","first-page":"811\u201317","DOI":"10.2307\/2530926","article-title":"Monte Carlo Confidence Intervals","volume":"40","author":"Buckland","year":"1984","journal-title":"Biometrics"},{"key":"R21-20260518","doi-asserted-by":"crossref","first-page":"97\u2013111","DOI":"10.1002\/jrsm.12","article-title":"A basic introduction to fixed-effect and random-effects models for meta-analysis","volume":"1","author":"Borenstein","year":"2010","journal-title":"Res Synth Methods"},{"key":"R22-20260518","doi-asserted-by":"crossref","first-page":"557\u201360","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"R23-20260518","doi-asserted-by":"crossref","first-page":"111784","DOI":"10.1016\/j.envres.2021.111784","article-title":"Effects of mobile phone usage on sperm quality\u2013no time-dependent relationship on usage: a systematic review and updated meta-analysis","volume":"202","author":"Kim","year":"2021","journal-title":"Environ Res"},{"key":"R24-20260518","doi-asserted-by":"crossref","first-page":"52\u201361","DOI":"10.1111\/jdv.19426","article-title":"The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials","volume":"38","author":"Yoon","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R25-20260518","doi-asserted-by":"crossref","first-page":"484\u201398","DOI":"10.1111\/aogs.14339","article-title":"Congenital anomalies and maternal age: a systematic review and meta-analysis of observational studies","volume":"101","author":"Ahn","year":"2022","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R26-20260518","doi-asserted-by":"crossref","first-page":"228\u201347","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R28-20260518","first-page":"1\u20136","article-title":"Nanoliposomal irinotecan in combination with leucovorin and 5-fluorouracil in advanced biliary tract cancers","volume":"16","author":"Allo","year":"2022","journal-title":"Mol Clin Oncol"},{"key":"R29-20260518","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/j.annonc.2022.04.142","article-title":"P-52 FOLFIRI or FOLFOX in second line of advanced biliary tract cancer: a retrospective analysis","volume":"33","author":"Balarine","year":"2022","journal-title":"Ann Oncol"},{"key":"R30-20260518","doi-asserted-by":"crossref","first-page":"iv72","DOI":"10.1016\/S0923-7534(20)30064-8","article-title":"P-0143 the role of chemotherapy in advanced biliary tract cancers: clinical experience from a specialist UK cancer centre","volume":"23","author":"Carb\u00f3","year":"2012","journal-title":"Ann Oncol"},{"key":"R31-20260518","doi-asserted-by":"crossref","first-page":"288\u201395","DOI":"10.1016\/j.ejca.2021.06.019","article-title":"A randomised phase II study of oxaliplatin\/5-FU (mFOLFOX) versus irinotecan\/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine\/cisplatin chemotherapy","volume":"154","author":"Choi","year":"2021","journal-title":"Eur J Cancer"},{"key":"R32-20260518","first-page":"240\u201343","article-title":"Efficacy and safety of folfox as a second-line chemotherapy for patients with locally advanced and\/or metastatic carcinoma gall bladder\u2013experience from a tertiary care center in India","volume":"40","author":"Dang","year":"2019","journal-title":"Indian J Med Paediatr Oncol"},{"key":"R33-20260518","doi-asserted-by":"crossref","first-page":"243\u201347","DOI":"10.1179\/1973947813Y.0000000133","article-title":"A phase II FOLFOX-4 regimen as second-line treatment in advanced biliary tract cancer refractory to gemcitabine\/cisplatin","volume":"26","author":"He","year":"2014","journal-title":"J Chemother"},{"key":"R34-20260518","doi-asserted-by":"crossref","first-page":"9680933","DOI":"10.1155\/2022\/9680933","article-title":"The efficacy and safety of hepatic arterial infusion chemotherapy based on FOLFIRI for advanced intrahepatic cholangiocarcinoma as second-line and successive treatment: a real-world study","volume":"2022","author":"Huang","year":"2022","journal-title":"Can J Gastroenterol Hepatol"},{"key":"R35-20260518","doi-asserted-by":"crossref","first-page":"757\u201362","DOI":"10.1007\/s00280-015-2691-1","article-title":"Phase II study of mFOLFOX3 (5-fluorouracil, leucovorin, oxaliplatin) as second-line treatment after gemcitabine failure in patients with unresectable\/metastatic biliary tract cancer","volume":"75","author":"Hwang","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"R36-20260518","article-title":"A phase II study of liposomal irinotecan-based chemotherapy with or without PD-1 inhibitor in patients with unresectable locally advanced or metastatic biliary tract cancer","author":"Ying","year":"2024","journal-title":"J Clin Oncol"},{"key":"R37-20260518","doi-asserted-by":"crossref","first-page":"322\u2013322","DOI":"10.1200\/jco.2014.32.3_suppl.322","article-title":"Second-line FOLFOX chemotherapy in patients with metastatic gallbladder cancer and cholangiocarcinoma","volume":"32","author":"Leal","year":"2014","journal-title":"J Clin Oncol"},{"key":"R38-20260518","doi-asserted-by":"crossref","first-page":"836\u201345","DOI":"10.1007\/s10637-020-01045-7","article-title":"Efficacy and safety of modified FOLFIRINOX as salvage therapy for patients with refractory advanced biliary tract cancer: a retrospective study","volume":"39","author":"Ye","year":"2021","journal-title":"Invest New Drugs"},{"key":"R39-20260518","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.3390\/cancers15092598","article-title":"Multidisciplinary treatment of patients with progressive biliary tract cancer after first-line gemcitabine and cisplatin: a single-center experience","volume":"15","author":"M\u00fcller","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R40-20260518","doi-asserted-by":"crossref","first-page":"1168\u201374","DOI":"10.1080\/0284186X.2016.1191670","article-title":"Efficacy of a sequential treatment strategy with GEMOX-based followed by FOLFIRI-based chemotherapy in advanced biliary tract cancers","volume":"55","author":"Sebbagh","year":"2016","journal-title":"Acta Oncol"},{"key":"R41-20260518","doi-asserted-by":"crossref","first-page":"475\u201381","DOI":"10.4103\/ijmr.IJMR_930_18","article-title":"Nab-paclitaxel: an effective third-line chemotherapy in patients with advanced, unresectable gallbladder cancer","volume":"152","author":"Talwar","year":"2020","journal-title":"Indian J Med Res"},{"key":"R42-20260518","doi-asserted-by":"crossref","first-page":"734\u201344","DOI":"10.1016\/S2468-1253(24)00119-5","article-title":"Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial","volume":"9","author":"Vogel","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"R43-20260518","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1016\/j.annonc.2023.04.287","article-title":"P-231 interim results of a phase II study of fluorouracil (FU), leucovorin (LV), and nanoliposomal irinotecan (nal-IRI) in previously treated advanced biliary tract cancer (NAPOLI-2)","volume":"34","author":"Weinberg","year":"2023","journal-title":"Ann Oncol"},{"key":"R44-20260518","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1186\/1471-2407-14-471","article-title":"Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis","volume":"14","author":"Gresham","year":"2014","journal-title":"BMC Cancer"},{"key":"R45-20260518","doi-asserted-by":"crossref","first-page":"8666","DOI":"10.1038\/s41598-018-26811-9","article-title":"The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis","volume":"8","author":"Tong","year":"2018","journal-title":"Sci Rep"},{"key":"R46-20260518","doi-asserted-by":"crossref","first-page":"76\u201385","DOI":"10.1007\/s10637-022-01322-7","article-title":"A prospective multicenter phase II study of FOLFIRINOX as a first-line treatment for patients with advanced and recurrent biliary tract cancer","volume":"41","author":"Takahara","year":"2023","journal-title":"Invest New Drugs"},{"key":"R48-20260518","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.3390\/cancers12113137","article-title":"Primary granulocyte colony-stimulating factor prophylaxis in metastatic pancreatic cancer patients treated with FOLFIRINOX as the first-line treatment","volume":"12","author":"Jung","year":"2020","journal-title":"Cancers"},{"key":"R49-20260518","doi-asserted-by":"crossref","first-page":"2473\u201385","DOI":"10.1111\/bcp.14356","article-title":"Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: a population pharmacokinetic\/pharmacodynamic approach","volume":"86","author":"Macaire","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R50-20260518","doi-asserted-by":"crossref","first-page":"2969\u201373","DOI":"10.2169\/internalmedicine.54.5325","article-title":"Efficacy of prophylactic G-CSF in patients receiving FOLFIRINOX: a preliminary retrospective study","volume":"54","author":"Terazawa","year":"2015","journal-title":"Internal Medicine"},{"key":"R51-20260518","article-title":"Primary prophylaxis with pegylated-granulocyte colony-stimulating factor for patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized phase II trial","author":"Lee","year":"2024","journal-title":"Am Soc Clin Oncol"},{"key":"R52-20260518","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11864-020-00767-3","article-title":"New treatment options for advanced biliary tract cancer","volume":"21","author":"Mizrahi","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"R53-20260518","doi-asserted-by":"crossref","first-page":"796\u2013807","DOI":"10.1016\/S1470-2045(20)30157-1","article-title":"Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R54-20260518","doi-asserted-by":"crossref","first-page":"671\u201384","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"key":"R55-20260518","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1038\/s41467-023-36399-y","article-title":"Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers","volume":"14","author":"Harding","year":"2023","journal-title":"Nat Commun"},{"key":"R56-20260518","doi-asserted-by":"crossref","first-page":"41\u201348","DOI":"10.1159\/000527525","article-title":"Clinical implications of BRCA mutations in advanced biliary tract cancer","volume":"101","author":"Kim","year":"2023","journal-title":"Oncology"},{"key":"R57-20260518","doi-asserted-by":"crossref","first-page":"82\u201394","DOI":"10.1016\/j.critrevonc.2019.06.001","article-title":"Prognostic immunohistochemical biomarkers of chemotherapy efficacy in biliary tract cancer: a systematic review and meta-analysis","volume":"141","author":"Belkouz","year":"2019","journal-title":"Crit Rev Oncol\/hematol"}],"container-title":["International Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T13:22:47Z","timestamp":1779110567000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JS9.0000000000003367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,5]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/js9.0000000000003367","relation":{},"ISSN":["1743-9159"],"issn-type":[{"value":"1743-9159","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,5]]},"assertion":[{"value":"2025-05-08","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}